While, to date, MEK inhibitors have conventionally been used in combination with BRAF inhibitors to reinforce the blockade of the MAP kinase (MAPK) growth signaling pathway in BRAF V600E-mutant cancers (including BTCs in the ROAR basket trial [48]), the rationale, in this case, is to use MAPK blockade for immune modulation in addition to the suppression of tumor growth, regardless of BRAF or KRAS mutational status. Here, BRAF is linked to neoplasm.